Teva Pharma (TEVA) Says it Remains Confident in Patient and Physician Loyalty to COPAXONE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Teva Pharma (TEVA) PT Lowered to $15 at Morgan Stanley
October 5, 2017 8:58 AM EDTMorgan Stanley lowered its price target on Teva Pharma (NYSE: TEVA) to $15.00 (from $16.00) while maintaining a Underweight rating.
... MoreTeva Pharma (TEVA) PT Lowered to $21 at Barclays; Generic Copaxone 40mg Approval 'Will Offset Some Contracting Strategies... Hurt Sentiment'
October 4, 2017 12:17 PM EDTBarclays lowered its price target on Teva Pharma (NYSE: TEVA) to $21.00 (from $23.00) while maintaining a Equalweight rating, following an update on the U.S. Specialty Pharmaceutical industry, as the FDA recently approved a generic Copaxone formulation.
Analyst Douglas Tsao notes a... More
Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market Perform
October 4, 2017 10:44 AM EDTCowen raised its price target on Mylan (NASDAQ: MYL) to $36.00 (from $30.00) while maintaining a Market Perform rating. Cowen updated its model to reflect a potential $800MM in generic Copaxone contribution in 2018, and then modestly declining with other competition.
With this approval the... More
